Webinars & Presentations

Discover how Akadeum’s microbubble isolation and MaxCyte’s electroporation boost T cell engineering—enhancing yield, viability, and transfection efficiency in non-viral CAR T workflows for more consistent, streamlined cell therapy development.

Megan Embrey, senior field application scientist at MaxCyte®, discusses how to streamline and enhance ex vivo cell engineering, focusing on CRISPR-Cas9 workflows.

Learn how MaxCyte’s Flow Electroporation® and Bruker’s Beacon® platform combine to accelerate CAR discovery. This webinar highlights a mammalian cell library workflow and functional single-cell screening to identify high-performance CARs efficiently.

In this DDN webinar, watch how transient transfection through MaxCyte’s electroporation platform can result in faster, more flexible cell-based screening assays, illustrated by case studies and real user datasets.

Watch how a streamlined, one-step process for the generation of universal CAR T cells can reduce costs and accelerate clinical translation, while maintaining potency and durability in hematological malignancy models.

In this session from the 2025 ISCT annual meeting, MaxCyte moderates a talk with partner Kamau Therapeutics, who shares insights from their journey to clinical trials for nula-cel, a next-generation gene correction therapy for sickle cell disease.

MaxCyte scientist Ashley Strickland-Dietz presents on protocols to improve non-viral engineering of CAR T cells, focusing on primary human T cells.

Watch MaxCyte researcher Isabel Daher present on optimizing VLP manufacturing for high yields in HEK cells using MaxCyte’s Flow Electroporation platform.

MaxCyte researcher Max Van Buskirk discusses how scalable electroporation can enhance transposon delivery in CAR T cell manufacturing workflows.

Watch a presentation about the benefits and challenges of cell-based assays, assay development with MaxCyte electroporation, and transiently transfected assay-ready cells.